A Phase 2a Open Label Study to Evaluate the Pharmacokinetics and Safety of Parathyroid Hormone hPTH(1-34) Administered via Transdermal Delivery and Subcutaneous Injection [Forteo Registered Trademark (teriparatide)] in Healthy Postmenopausal Women
Phase of Trial: Phase II
Latest Information Update: 08 Jun 2016
At a glance
- Drugs Teriparatide (Primary)
- Indications Osteoporosis
- Focus Pharmacokinetics
- Sponsors Corium International
- 28 Jul 2015 Corium plans to submit the full results of this Phase 2a study for presentation at a future scientific meeting following completion of ongoing analysis.
- 28 Jul 2015 Topline results published in Corium International media release.
- 14 Apr 2015 Status changed from planning to recruiting as reported by Australian & NZ Clinical Trials Register.